Chinese scientists publish promising findings on clinical trials involving Avasimibe, which has shown to inhibit tumour growth by targeting FoxM1-AKR1C1 in osteosarcoma
Avasimibe Inhibits Tumor Growth by Targeting FoxM1-AKR1C1 in Osteosarcoma
Avasimibe inhibits tumor growth